PMID- 22941034
OWN - NLM
STAT- MEDLINE
DCOM- 20140407
LR  - 20211021
IS  - 1618-7601 (Electronic)
IS  - 1618-7598 (Linking)
VI  - 14
IP  - 5
DP  - 2013 Oct
TI  - Utility elicitation study in the UK general public for late-stage chronic 
      lymphocytic leukaemia.
PG  - 749-59
LID - 10.1007/s10198-012-0419-2 [doi]
AB  - OBJECTIVES: In the United Kingdom (UK), chronic lymphocytic leukaemia (CLL) makes 
      up 40 % of all leukaemias in patients over 65 years. The study objective was to 
      obtain societal preferences in the UK for "progression-free" and "progressive" 
      states of late-stage CLL, refractory to current first and second line regimens. 
      Preferences were also obtained for selected treatment-related adverse events 
      (AEs). METHODS: A utility elicitation study, using the time trade-off (TTO) 
      method, was conducted by face-to-face interviews with 110 subjects for a baseline 
      disease state (before treatment), three primary disease states [progression-free 
      survival (PFS) and treatment responder, PFS and treatment non-responder and 
      disease progression], and 4 AE sub-states (PFS responder with thrombocytopenia, 
      neutropenia, and infection, and PFS non-responder with infection). TTO scores 
      were converted into utility values, and disutilities were calculated for AEs. 
      Visual analogue scale (VAS) scores were obtained. RESULTS: The primary disease 
      state mean TTO utility scores were: baseline: 0.549; PFS response: 0.671; PFS 
      non-response: 0.394; and progression: 0.214. The mean TTO utility (disutility) 
      scores for the AEs were: PFS response with thrombocytopenia, 0.563 (-0.108), 
      neutropenia, 0.508 (-0.163), and infection, 0.476 (-0.195); PFS non-response with 
      infection, 0.333 (-0.061). The VAS results were in line with the TTO results. 
      CONCLUSIONS: The utility was higher for the PFS state than baseline, but 
      decreased below baseline in non-response and disease progression states. AEs had 
      an impact on utility within the PFS response state. The severe infection AE had a 
      greater impact on utilities for the responding to treatment state compared to the 
      non-responder state.
FAU - Tolley, Keith
AU  - Tolley K
AD  - Tolley Health Economics, Buxton, UK.
FAU - Goad, Catherine
AU  - Goad C
FAU - Yi, Yunni
AU  - Yi Y
FAU - Maroudas, Penny
AU  - Maroudas P
FAU - Haiderali, Amin
AU  - Haiderali A
FAU - Thompson, Gwilym
AU  - Thompson G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120901
PL  - Germany
TA  - Eur J Health Econ
JT  - The European journal of health economics : HEPAC : health economics in prevention 
      and care
JID - 101134867
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Confidence Intervals
MH  - *Consumer Behavior
MH  - Cross-Sectional Studies
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - *Health Status
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - *Quality of Life
MH  - United Kingdom
MH  - Young Adult
EDAT- 2012/09/04 06:00
MHDA- 2014/04/08 06:00
CRDT- 2012/09/04 06:00
PHST- 2011/12/12 00:00 [received]
PHST- 2012/07/30 00:00 [accepted]
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2014/04/08 06:00 [medline]
AID - 10.1007/s10198-012-0419-2 [doi]
PST - ppublish
SO  - Eur J Health Econ. 2013 Oct;14(5):749-59. doi: 10.1007/s10198-012-0419-2. Epub 
      2012 Sep 1.